Matt Gethers

From OpenWetWare

(Difference between revisions)
Jump to: navigation, search
(20.109 Work)
Current revision (07:22, 18 February 2009) (view source)
(UROP Projects)
 
(38 intermediate revisions not shown.)
Line 1: Line 1:
-
I'm currently a sophomore in course 20. When I'm behaving myself, I'm allowed to work in the [[Endy Lab]] at [http://mit.edu MIT]. I will be documenting my UROP projects [[Endy:Translation demand | here]]. I will put my 20.109 work directly below.
+
I'm currently a sophomore in course 20. When I'm behaving myself, I'm allowed to work in the [[Endy Lab]] at [http://mit.edu MIT]. I have links to my UROP projects and 20.109 work directly below.
 +
 
 +
 
 +
==UROP Projects==
 +
 
 +
[[/20.380 HIV Project|20.380 HIV Project]]
 +
 
 +
[[/Articles of General Interest| Articles of General Interest]]
 +
 
 +
[[/Articles to Read|Articles to Read]]
 +
 
 +
[[Endy:Translation demand | Translation Demand]]
 +
 
 +
[http://bcanton.private.openwetware.org/wiki/Lab_Notebook/Matt/Mitochondria_Project Mitochondrial Engineering]
 +
 
 +
[[/CRI, Thailand| CRI Thailand]]
 +
 
 +
[[/Matt's Stanford Freezer Stocks|Matt's Stanford Freezer Stocks]]
 +
 
 +
[[/OWW Syntax| OWW Syntax]]
 +
 
 +
[[/Eloranta Ideas|Eloranta Ideas]]
==20.109 Work==
==20.109 Work==
-
===M13 Engineering Ideas===
+
*[[User:Mgethers/M13 Engineering Ideas|M13 Engineering Ideas]]
 +
 
 +
*[[User:Mgethers/2.27.06 Ligation and Transformation Data|2.27.06 Ligation and Transformation Data]]
-
{| {{table}}
+
*[[User:Mgethers/2.27.09 Refactoring Work|2.27.09 Refactoring Work]]
-
| align="center" style="background:#f0f0f0;"|'''Gene'''
+
-
| align="center" style="background:#f0f0f0;"|'''Modification'''
+
-
|-
+
-
| X||Extract from gene II.  
+
-
|-
+
-
| II||Extract gene X.  
+
-
|-
+
-
| V|| Add some base pairs between V and VII to allow for a restriction site.
+
-
|-
+
-
| VII||Separate from gene IX.  
+
-
|-
+
-
| III||Change the GTG to ATG Start?
+
-
|-
+
-
| VI|| Add some base pairs between III and VI and VI anda I to allow for restriction sites.
+
-
|-
+
-
| I||Separate from genes IV and XI.
+
-
|-
+
-
| XI||Separate from genes I and IV.
+
-
|-
+
-
| IV||Separate from genes I and XI.
+
-
|-
+
-
| M13 ORI 1 & 2|| Are two ORIs necessary? If so, can they be consolidated?
+
-
|-
+
-
| KanR|| Possible to remove bps 6600 - 7100 upstream of KanR? Does this DNA have functional significance?
+
-
|-}
+
 +
*[[:Image:4.3.07_Primer_Design_Team_Purple.doc|4.3.07_Primer_Design_Team_Purple.doc]]
-
Extractions, separations, etc. include ensuring that each gene has its own promoter, RBS, terminator, and any other pertinent regulatory sequences.
+
*[[User:Mgethers/Research Proposal|Research Proposal]]
-
In addition to separating the genes, it would also be wise to develop or utilize/modify an existing system like [http://parts.mit.edu/registry/index.php/Main_Page Biobricks] to build the genome so that convenient restriction sites exist between the genes so they can be easily removed or replaced.
+
==Class projects==
 +
[[/20.310 Term Paper| 20.310 Term Paper]]
-
I used [http://www.neb.com/nebecomm/tech_reference/restriction_enzymes/sequences/m13ko7.txt the following annotation] to locate and design changes to the genome.
+
==20.310 Project==
-
===Ligation and Transformation Results===
+
<biblio>
 +
#Galkin pmid=17449671
 +
#Carragher pmid=3351926
 +
#Carragher2 pmid=3351927
 +
#Carragher3 pmid=3351930
 +
#Turner pmid=12638863
 +
#Wang pmid=11812133
 +
</biblio>
-
{| {{table}}
+
Treatments exist for preventive and palliative treatment of sickle cell episodes, but no treatment has yet been developed to mitigate the effects of an attack once it has started. We need a way of dealing with Hbs fibers once they have polymerized. We feel we can develop a treatment for an ongoing attack by addressing the biomechanical basis of the pathology.
-
| align="center" style="background:#f0f0f0;"|'''DNA Ligation Sample'''
+
-
| align="center" style="background:#f0f0f0;"|'''Expected Number of Transformants'''
+
-
| align="center" style="background:#f0f0f0;"|'''Observed Number of Transformants'''
+
-
|-
+
-
| Control Plasmid||Many||1184
+
-
|-
+
-
| BKB with cocktail but no ligase||0||0
+
-
|-
+
-
| BKB with ligase and cocktail||0||6
+
-
|-
+
-
| BKB with insert and ligase and cocktail #1||A few||0-1
+
-
|-
+
-
| BKB with insert and ligase and cocktail #2||A few||5
+
-
|-}
+

Current revision

I'm currently a sophomore in course 20. When I'm behaving myself, I'm allowed to work in the Endy Lab at MIT. I have links to my UROP projects and 20.109 work directly below.


Contents

UROP Projects

20.380 HIV Project

Articles of General Interest

Articles to Read

Translation Demand

Mitochondrial Engineering

CRI Thailand

Matt's Stanford Freezer Stocks

OWW Syntax

Eloranta Ideas

20.109 Work

Class projects

20.310 Term Paper

20.310 Project

  1. Galkin O, Pan W, Filobelo L, Hirsch RE, Nagel RL, and Vekilov PG. . pmid:17449671. PubMed HubMed [Galkin]
  2. Carragher B, Bluemke DA, Gabriel B, Potel MJ, and Josephs R. . pmid:3351926. PubMed HubMed [Carragher]
  3. Bluemke DA, Carragher B, Potel MJ, and Josephs R. . pmid:3351927. PubMed HubMed [Carragher2]
  4. Carragher B, Bluemke DA, Becker M, McDade WA, Potel MJ, and Josephs R. . pmid:3351930. PubMed HubMed [Carragher3]
  5. Jones CW, Wang JC, Ferrone FA, Briehl RW, and Turner MS. . pmid:12638863. PubMed HubMed [Turner]
  6. Wang JC, Turner MS, Agarwal G, Kwong S, Josephs R, Ferrone FA, and Briehl RW. . pmid:11812133. PubMed HubMed [Wang]
All Medline abstracts: PubMed HubMed

Treatments exist for preventive and palliative treatment of sickle cell episodes, but no treatment has yet been developed to mitigate the effects of an attack once it has started. We need a way of dealing with Hbs fibers once they have polymerized. We feel we can develop a treatment for an ongoing attack by addressing the biomechanical basis of the pathology.

Personal tools